Predicting PAM50 subtypes from whole slide images of prostate cancer biopsies

e17001Background: Computational analysis of digitized pathological images has been shown to have diagnostic and prognostic applications. Recent research suggests that molecular features, previously defined at the genomic level, might be additionally recognized. In prostate cancer, transcriptomic PAM...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 42; no. 16_suppl; p. e17001
Main Authors Ayad, Marina, Saft, Madeline, Li, Eric Victor, Kumar, Sai, Neill, Clayton, Patel, Hiten D., Schaeffer, Edward M., Liu, Yang, Davicioni, Elai, Yang, Ximing J, Cooper, Lee A.D., Ross, Ashley
Format Journal Article
LanguageEnglish
Published American Society of Clinical Oncology 01.06.2024
Online AccessGet full text
ISSN0732-183X
1527-7755
DOI10.1200/JCO.2024.42.16_suppl.e17001

Cover

Abstract e17001Background: Computational analysis of digitized pathological images has been shown to have diagnostic and prognostic applications. Recent research suggests that molecular features, previously defined at the genomic level, might be additionally recognized. In prostate cancer, transcriptomic PAM50 molecular subtypes may correlate with patient response to systemic therapy. Here we investigate whether computational analysis of digital prostate biopsy slides can predict PAM50 category. Methods: Our study utilized digitized images of 704 prostate biopsy slides from 336 patients with prostate cancer at Northwestern Memorial Hospital with Decipher testing (Veracyte, Inc San Diego, CA). All slides analyzed contain carcinoma with the majority being primary Gleason pattern 3 (545 out of 704). Hematoxylin and eosin stained slides were scanned on a Leica GT450 scanner at 40x magnification. PAM50 subtypes were derived from the Decipher Genomic Resource Information Database (GRID). Data were split at the subject level using 80% for training, 10% for validation, and 10% for evaluation, facilitating model development and assessment. We devised a model comprising two decoupled parts: a multi-instance learning model that utilizes a multi-class attention mechanism to explore relevant class-specific information from slides, and a pre-trained network to extract high-dimensional semantic features from the tiles of WSIs. The model trained based on the WSIs of the training set to predict PAM50 subtypes (luminal A, luminal B, and basal). This attention-based training approach allowed the model to capture relevant patterns and information present in the WSIs. Following the training phase, the model was subsequently evaluated on the testing set. Results: Model AUC on the evaluation set was 0.78. Among evaluation set misclassifications, no luminal samples were misclassified as basal subtype. Conclusions: Our investigation provides preliminary results on the ability to predict RNA expression-based subtypes from prostate cancer biopsy histology. This approach may help to preserve tissue, minimize costs, and decrease turnaround time associated with molecular testing in prostate cancer while offering patients with prostate cancer opportunities for precision medicine.
AbstractList e17001Background: Computational analysis of digitized pathological images has been shown to have diagnostic and prognostic applications. Recent research suggests that molecular features, previously defined at the genomic level, might be additionally recognized. In prostate cancer, transcriptomic PAM50 molecular subtypes may correlate with patient response to systemic therapy. Here we investigate whether computational analysis of digital prostate biopsy slides can predict PAM50 category. Methods: Our study utilized digitized images of 704 prostate biopsy slides from 336 patients with prostate cancer at Northwestern Memorial Hospital with Decipher testing (Veracyte, Inc San Diego, CA). All slides analyzed contain carcinoma with the majority being primary Gleason pattern 3 (545 out of 704). Hematoxylin and eosin stained slides were scanned on a Leica GT450 scanner at 40x magnification. PAM50 subtypes were derived from the Decipher Genomic Resource Information Database (GRID). Data were split at the subject level using 80% for training, 10% for validation, and 10% for evaluation, facilitating model development and assessment. We devised a model comprising two decoupled parts: a multi-instance learning model that utilizes a multi-class attention mechanism to explore relevant class-specific information from slides, and a pre-trained network to extract high-dimensional semantic features from the tiles of WSIs. The model trained based on the WSIs of the training set to predict PAM50 subtypes (luminal A, luminal B, and basal). This attention-based training approach allowed the model to capture relevant patterns and information present in the WSIs. Following the training phase, the model was subsequently evaluated on the testing set. Results: Model AUC on the evaluation set was 0.78. Among evaluation set misclassifications, no luminal samples were misclassified as basal subtype. Conclusions: Our investigation provides preliminary results on the ability to predict RNA expression-based subtypes from prostate cancer biopsy histology. This approach may help to preserve tissue, minimize costs, and decrease turnaround time associated with molecular testing in prostate cancer while offering patients with prostate cancer opportunities for precision medicine.
e17001 Background: Computational analysis of digitized pathological images has been shown to have diagnostic and prognostic applications. Recent research suggests that molecular features, previously defined at the genomic level, might be additionally recognized. In prostate cancer, transcriptomic PAM50 molecular subtypes may correlate with patient response to systemic therapy. Here we investigate whether computational analysis of digital prostate biopsy slides can predict PAM50 category. Methods: Our study utilized digitized images of 704 prostate biopsy slides from 336 patients with prostate cancer at Northwestern Memorial Hospital with Decipher testing (Veracyte, Inc San Diego, CA). All slides analyzed contain carcinoma with the majority being primary Gleason pattern 3 (545 out of 704). Hematoxylin and eosin stained slides were scanned on a Leica GT450 scanner at 40x magnification. PAM50 subtypes were derived from the Decipher Genomic Resource Information Database (GRID). Data were split at the subject level using 80% for training, 10% for validation, and 10% for evaluation, facilitating model development and assessment. We devised a model comprising two decoupled parts: a multi-instance learning model that utilizes a multi-class attention mechanism to explore relevant class-specific information from slides, and a pre-trained network to extract high-dimensional semantic features from the tiles of WSIs. The model trained based on the WSIs of the training set to predict PAM50 subtypes (luminal A, luminal B, and basal). This attention-based training approach allowed the model to capture relevant patterns and information present in the WSIs. Following the training phase, the model was subsequently evaluated on the testing set. Results: Model AUC on the evaluation set was 0.78. Among evaluation set misclassifications, no luminal samples were misclassified as basal subtype. Conclusions: Our investigation provides preliminary results on the ability to predict RNA expression-based subtypes from prostate cancer biopsy histology. This approach may help to preserve tissue, minimize costs, and decrease turnaround time associated with molecular testing in prostate cancer while offering patients with prostate cancer opportunities for precision medicine.
Author Ayad, Marina
Neill, Clayton
Yang, Ximing J
Patel, Hiten D.
Saft, Madeline
Kumar, Sai
Cooper, Lee A.D.
Liu, Yang
Ross, Ashley
Li, Eric Victor
Schaeffer, Edward M.
Davicioni, Elai
Author_xml – sequence: 1
  givenname: Marina
  surname: Ayad
  fullname: Ayad, Marina
– sequence: 2
  givenname: Madeline
  surname: Saft
  fullname: Saft, Madeline
– sequence: 3
  givenname: Eric Victor
  surname: Li
  fullname: Li, Eric Victor
– sequence: 4
  givenname: Sai
  surname: Kumar
  fullname: Kumar, Sai
– sequence: 5
  givenname: Clayton
  surname: Neill
  fullname: Neill, Clayton
– sequence: 6
  givenname: Hiten D.
  surname: Patel
  fullname: Patel, Hiten D.
– sequence: 7
  givenname: Edward M.
  surname: Schaeffer
  fullname: Schaeffer, Edward M.
– sequence: 8
  givenname: Yang
  surname: Liu
  fullname: Liu, Yang
– sequence: 9
  givenname: Elai
  surname: Davicioni
  fullname: Davicioni, Elai
– sequence: 10
  givenname: Ximing J
  surname: Yang
  fullname: Yang, Ximing J
– sequence: 11
  givenname: Lee A.D.
  surname: Cooper
  fullname: Cooper, Lee A.D.
– sequence: 12
  givenname: Ashley
  surname: Ross
  fullname: Ross, Ashley
BookMark eNqNkF1LwzAYhYNMcJv-h4DXrW-SZmnxQsbwk43tQsG7kLZvtmrWlqSj7N_bMb336sDhnMPhmZBR3dRIyC2DmHGAu7fFOubAkzjhMZvpcGhbFyNTAOyCjJnkKlJKyhEZgxI8Yqn4vCKTEL6GQJIKOSarjceyKrqq3tLNfCWBhkPeHVsM1PpmT_td45AGV5VIq73ZDn5jaeub0JkOaWHqAj3Nq6YNFYZrcmmNC3jzq1Py8fT4vniJluvn18V8GRUMUhalQoEqmEHDuVTSzGxmrRK54GUmpSjB8CwtVYkzSHIONheo0owr4EZZkFZMyf15txiOBI9Wt35454-agT6R0QMZfSKjE67_yOgzmaH9cG73jevQh2936NHrHRrX7f618AMpK3Cl
ContentType Journal Article
Copyright 2024 by American Society of Clinical Oncology
Copyright_xml – notice: 2024 by American Society of Clinical Oncology
DBID AAYXX
CITATION
DOI 10.1200/JCO.2024.42.16_suppl.e17001
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList
CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1527-7755
EndPage e17001
ExternalDocumentID 10_1200_JCO_2024_42_16_suppl_e17001
458852
Genre meeting-report
GroupedDBID ---
.55
0R~
18M
34G
39C
4.4
53G
5GY
5RE
8F7
AAQQT
AARDX
AAWTL
AAYEP
ABJNI
ABOCM
ACGFO
ACGFS
ACGUR
ADBBV
AEGXH
AENEX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BYPQX
C45
CS3
DIK
EBS
EJD
F5P
F9R
FBNNL
FD8
GX1
HZ~
IH2
IPNFZ
K-O
KQ8
L7B
LSO
MJL
N9A
O9-
OK1
OVD
OWW
P2P
QTD
R1G
RHI
RIG
RLZ
RUC
SJN
TEORI
TR2
TWZ
UDS
VVN
WH7
X7M
YFH
YQY
2WC
AAYXX
ABBLC
CITATION
ID FETCH-LOGICAL-c1081-83707c1aea22575a6f9ff73b32d9553d0a298d7de604b20fb3e7892702a7f05f3
ISSN 0732-183X
IngestDate Tue Jul 01 01:38:02 EDT 2025
Wed Apr 16 02:24:32 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 16_suppl
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1081-83707c1aea22575a6f9ff73b32d9553d0a298d7de604b20fb3e7892702a7f05f3
Notes Abstract Disclosures
PageCount 91
ParticipantIDs crossref_primary_10_1200_JCO_2024_42_16_suppl_e17001
wolterskluwer_health_10_1200_JCO_2024_42_16_suppl_e17001
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20240601
2024-06-01
PublicationDateYYYYMMDD 2024-06-01
PublicationDate_xml – month: 6
  year: 2024
  text: 20240601
  day: 1
PublicationDecade 2020
PublicationTitle Journal of clinical oncology
PublicationTitleAbbrev ASCO MEETING ABSTRACTS
PublicationYear 2024
Publisher American Society of Clinical Oncology
Publisher_xml – name: American Society of Clinical Oncology
SSID ssj0014835
Score 2.4558628
Snippet e17001Background: Computational analysis of digitized pathological images has been shown to have diagnostic and prognostic applications. Recent research...
e17001 Background: Computational analysis of digitized pathological images has been shown to have diagnostic and prognostic applications. Recent research...
SourceID crossref
wolterskluwer
SourceType Index Database
Publisher
StartPage e17001
Title Predicting PAM50 subtypes from whole slide images of prostate cancer biopsies
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&DO=10.1200/JCO.2024.42.16_suppl.e17001
Volume 42
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1527-7755
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0014835
  issn: 0732-183X
  databaseCode: KQ8
  dateStart: 19990101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals - Free Access to All
  customDbUrl:
  eissn: 1527-7755
  dateEnd: 20241101
  omitProxy: true
  ssIdentifier: ssj0014835
  issn: 0732-183X
  databaseCode: DIK
  dateStart: 20040101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1527-7755
  dateEnd: 20241101
  omitProxy: true
  ssIdentifier: ssj0014835
  issn: 0732-183X
  databaseCode: GX1
  dateStart: 20040101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swEBahgzIYY-s21v1CsNEX15kty3byGLKVbmsSQ9ORNyPJcjFjSYgTSvaP7d_bnWXFDh2j64sJNhay7svdSfq-EyEfFFOZJwLlSsaUy6XirvRE7kbaU3HIBCTJuDQwGkfnV_zrLJx1Or9brKXNWnbVr7_qSu5jVbgHdkWV7H9Ydtco3IDfYF-4goXheicbJyvcZqmIy8lgFHpOuZG4ploa1cgNnn3rQCKZaaf4Ka5Nfdkl6jwgw0S-l9IrRxaLZWmphLfT1J10cjFXe0vwg61Bxwhm2_Odc78Uea0BylDpvoPNRWG9rvO9UKbE8T7H-1IU7SUIxhuqVIv1j-6oJpoikcR2btLunPFrccBc8CQzE4Jqv8tiSPRNxV7rmDlrAzBKSzzntOVsNdYW9Fuhu7lxKzAwc-b1cNLFD-hy1rUNdtvNtMtxjydp8uksvfgy_rb_sIr-qPANIfY_YBBOqjNDZjtuEUwxzcmu9ksPyfu6Ex__0YW91OjRzQLpEuWPSi3RynmmT8jjGgV0YJD3lHT0_Igcjmo6xhE5SUzh8-0pnTY6vvKUntCkKYm-fUZGDVJphVRqkUoRqbRCKq2QSg1S6SKnFqnUIJVapD4nV2efp8Nztz7Iw1U-pJwuFliKlS-0gOgRhyLKcacgkAHL-mEYgLNg_V4WZzryuGReLgMd9_qolBRx7oV58IIczBdz_ZJQHx7hpL3vhxn3hO5HMmS8B4lrT0Ej6phwO4bp0tRrSXGey3DTdjhJcehTzlI79KkZ-mPS2xvv1KiQ7_Lqq_u_-po8bP5Ob8jBerXRbyHHXct3FZ7-AEBBpos
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predicting+PAM50+subtypes+from+whole+slide+images+of+prostate+cancer+biopsies&rft.jtitle=Journal+of+clinical+oncology&rft.au=Ayad%2C+Marina&rft.au=Saft%2C+Madeline&rft.au=Li%2C+Eric+Victor&rft.au=Kumar%2C+Sai&rft.date=2024-06-01&rft.pub=American+Society+of+Clinical+Oncology&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=42&rft.issue=16_suppl&rft.spage=e17001&rft.epage=e17001&rft_id=info:doi/10.1200%2FJCO.2024.42.16_suppl.e17001&rft.externalDBID=NO_PDF_LINK&rft.externalDocID=458852
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon